No products in the cart.
Summit Is in Talks for $15 Billion Partnership With AstraZeneca
AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion over time to license a lung-cancer drug, according to people familiar with the matter.